Table 3 Risk factors for PJP pneumonia in total population (univariate and multivariate analysis).
From: Risk factors for Pneumocystis jirovecii pneumonia (PJP) in kidney transplantation recipients
Variable | Univariate | Multivariate | |||
|---|---|---|---|---|---|
PJP negative (n = 482) | PJP positive (n = 18) | P | OR (95% CI) | P | |
Men, sex, N (%) | 292(60.6) | 15 (83.3) | 0.052 | 3.93 (1.00–15.47) | 0.050 |
Age, years (median, range) | 47.0 (18.0–71.0) | 53.0 (25.0–65.0) | 0.076 | 1.02 (0.96–1.08) | 0.536 |
Follow up duration, month (median, range) | 36.2 (18.7–54.6) | 36.3 (18.4–54.5) | 0.688 | ||
BMI, kg/m2 (median, IQR) | 22.2 (20.1–24.2) | 21.1 (18.5–23.7) | 0.200 | 0.94 (0.78–1.14) | 0.525 |
KT type, living, N (%) | 314 (65.1) | 8 (44.4) | 0.072 | 0.50(0.17–1.44) | 0.198 |
Re-transplantation, N (%) | 40 (8.3) | 1 (5.6) | 1.000 | ||
Ever smoker, N (%) | 133 (27.6) | 6 (33.3) | 0.594 | ||
Primary underlying disease, N (%) | 0.102 | ||||
Polycystic kidney | 15 (3.1) | 2 (11.1) | |||
HTN | 194 (40.2) | 4 (22.2) | |||
DM | 81 (16.8) | 4 (22.2) | |||
IgA nephropathy | 60 (12.4) | 3 (16.7) | |||
Autoimmune disease | 6 (1.2) | 1 (5.6) | |||
Chronic Glomerulonephritis | 35 (7.3) | 1 (5.6) | |||
Nephrotic syndrome | 40 (8.3) | 1 (5.6) | |||
Recurrent pyelonephritis/other | 19 (3.9) | 2 (11.1) | |||
Unknown | 32 (6.6) | 0 (0) | |||
Acute graft rejection, N (%) | 97 (20.1) | 15 (83.3) | <0.001 | 11.81 (3.06–45.57) | <0.001 |
CMV infection, N (%) | 62 (12.9) | 11 (61.1) | <0.001 | 5.42 (1.69–17.39) | 0.005 |
BK virus infection, N (%) | 88 (18.3) | 7 (38.9) | 0.058 | ||
Using DM medication, N (%) | 126 (26.1) | 9 (50.0) | 0.032 | 1.59 (0.51–5.02) | 0.427 |
History of TB, N (%) | 29 (6.0) | 1 (5.6) | 1.000 | ||
Lowest lymphocyte, 103/μ \(\ell \) (median, IQR) | 0.7 (0.4–1.2) | 0.3 (0.1–0.6) | 0.007 | 1.21 (0.83–1.70) | 0.290 |
Immunosuppressive agent, N (%) | 0.710 | ||||
Cyclosporine based regimen | 59 (12.2) | 1 (5.6) | |||
Tacrolimus based regimen | 423 (87.8) | 17 (94.4) | |||
